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Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous 
system, in which proinflammatory cytokines play a critical role in the pathogenic formation 
of lesions. Caspase-1 is a cysteine protease that proteolytically cleaves precursors of 
interleukin (IL)-18 and IL-1β and turns them into their active forms. These inflammatory 
cytokines play an important role in the development of MS. The aim of the present study 
was the investigation of caspase-1 and its downstream products, IL-18 and IL-1β, in 
relapsing-remitting MS (RRMS) patients. 
In this study, we used an ELISA assay to measure serum and cellular caspase-1 and serum 
levels of IL-18 and IL-1β in RRMS patients in the relapse phase (n=23) and healthy age-and 
gender-matched controls (n=19). 
We observed that the caspase-1 level was significantly increased in the serum of MS 
patients compared to the healthy controls (p=0.03). Although caspase-1 concentration in the 
lysate of peripheral blood mononuclear cells (PBMCs) was higher than serum among 
patients and controls (p<0.001), no significant difference was found in cellular levels of 
caspase-1 between the two groups. There was no significant difference in serum levels of  
IL-18 and IL-1β between patients and controls.  
In this study, we found an elevation of extracellular caspase-1, as a reflection of its 
intracellular level, in the serum of RRMS patients during the relapse phase. Therefore, it 
suggests being a suitable peripheral biomarker of disease activity in multiple sclerosis. 
 




Multiple sclerosis (MS) is an inflammatory  
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demyelination disease of the central nervous system 
(CNS) which occurs mainly in 20-40-year-old adults 
and is more prevalent in women. In a recent meta-
analysis study, the prevalence and incidence of MS in 
Iran were estimated 29.3/100,000 and 3.4/100,000 
respectively.
1
 A variety of immunological factors have 
been investigated to understand the etiology of the 
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disease but it has remained unknown thus far. 
The nucleotide-binding oligomerization domain 
(NOD), leucine-rich repeat (LRR)- and pyrin domain-
containing protein 3 (NLRP3) forms an inflammasome 
in response to a wide variety of bacterial and viral 
components. The NLRP3 inflammasome formation 
activates caspase-1 through the proteolytic cleavage of 
procaspase-1. Activation of caspase-1 leads to the 
processing and secretion of the pro-inflammatory 
cytokines, interleukin-1β (IL-1β) and IL-18. IL-1β and 
IL-18 play important roles in the induction of adaptive 
immune responses by regulating the differentiation and 
activation of T-helper 1 (Th1) and T-helper 17 (Th17) 
cells which are pathogenic in multiple sclerosis. IL-18 
also promotes Th1 cell polarization via inducing 
interferon-γ (IFN-γ) production by activated T cells and 
natural killer (NK) cells. Recent studies have shown 
that IL-1 and IL-18 synergized with IL-23 to induce IL-
17 production from pre-committed Th17 cells.
2
 
The evidence for the role of caspase-1 in MS was 
mainly provided by studies on experimental 
autoimmune encephalomyelitis (EAE), an animal 
model of MS. Caspase-1 deficient mice have shown a 
reduced level of IL-18 cytokine and are protected from 
EAE incidence and severity. Moreover, during EAE, 
caspase-1 is up-regulated at the protein and 
transcriptional levels in the blood, also in inflammatory 
and neuronal cells, which is parallel with the 
upregulation of pro-inflammatory cytokines such as IL-
1β, IFN-γ, Tumor necrosis factor (TNF)-α, and IL-6. 
Nlrp3, caspase-1, or IL-18 knockout mice exhibited 
delayed neuroinflammation, demyelination, and 
oligodendrocyte loss in the EAE.3 IL-1β and IL-18 
were demonstrated to promote Th17 cells 
differentiation and contribute to Th17-driven 
exacerbation of EAE.
4
 Interestingly, IL-18 knockout 
mice showed enhanced re-myelination, over-expression 
of IL- 18 base pair (bp), an endogenous inhibitor of IL-
18, and reduced Th17 responses in the CNS and EAE 
severity as well.
5
 Furthermore, Nlrp3 and IL-18 
knockout mice had similarly reduced IFN-γ/IL-17 
production and EAE disease severity.
6
 
Consistent with the results in a mouse model of 
multiple sclerosis, it was reported that the expression of 
caspase-1, IL-1β, and IL-18 were elevated in MS 
plaques and/or cells from MS patients.
7
 Caspase-1-
positive neurons and inflammatory cells were also 
observed during the relapse phase of the disease. 
Increased caspase-1 mRNA levels have been shown in 
PBMCs from MS patients in a week preceding an acute 
attack and it was correlated with the number of new but 
not persistent gadolinium-enhancing brain Magnetic 
resonance imaging (MRI) lesions. 
Since the activation of NLRP3 exacerbates CNS 
inflammation probably via caspase-1, IL-18, and IL-1β, 
we measured caspase-1, IL-1β, and IL-18 levels in 
RRMS patients in the relapse phase. We believe that 
the results can be very helpful to understand the 
pathogenesis of the disease. 
 
MATERIALS AND METHODS 
 
Twenty-three RRMS patients (18 Females, 5 Males; 
mean age: 32.3±9.6 years old; EDSS: 2±0.5) with 
clinically definite MS were examined in this study. The 
diagnosis has been performed according to McDonald's 
criteria.
8
 All patients met our assumed inclusion criteria 
of not being treated with any kind of IFN-β and 
corticosteroid for at least three previous months and 
had a history of at least two relapses at the time of 
initial sampling. All Patients were in the relapse phase 
and disease activity was assessed by an experienced 
neurologist. All of the patients were referred to 
Amiralam general hospital affiliated to Tehran 
University of Medical Sciences (TUMS). 
Nineteen ethnically sex and age-matched healthy 
controls (14 Female, 5male, mean age: 29.3±7.2 years 
old), were examined in this study. By completing the 
questionnaire, we could rule out any history of MS or 
autoimmune/inflammatory diseases in healthy controls. 
All patients and controls were of Iranian origin. The 
study was conducted according to the ethical guidelines 
of our institution (Grant No. 90-03-30-15044). 
Informed consents were obtained from all participants 
before the study. 
Peripheral blood mononuclear cells (PBMCs) were 
isolated using Lymphodex (inno-train, Germany). 
Isolated serum and PBMCs were stored at -80°c until 
the testing day. 
 
Caspase-1, IL-1β, and IL-18 Assays 
Caspase-1, IL-1β, and IL-18 were investigated in 
the serum of patients and controls by using the ELISA 
kit (Uscn Life Science Inc., PRC). It was a sandwich 
enzyme immunoassay method. According to the 
manufacturer's instruction, the intended biomarkers (if 
present) bonded to its specific antibody (pre-coated in 
the wells), biotin-conjugated antibody, and avidin 
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conjugated to horseradish peroxidase (HRP) was added 
respectively. After adding the substrate (
Tetramethylbenzidine, TMB), the reaction 
terminated by the addition of a sulphuric acid solution.
The plates were then read at 450 nm using a
reader (spectraMax microplate reader, USA)
measurement of cellular caspase-1, PBMCs were
frozen and thawed three times and centrifuged. 
Caspase-1 was then measured in 
Furthermore, the concentrations of caspase
and IL-18 were determined by comparing the O.D of 
the samples to the standard curve. The detection limits 
of IL-18, IL-β and Caspase-1 were 5.9 
pg/mL and 0.115 ng/mL, respectively. 
 
Statistical Analysis  
Data are expressed as mean±SD. Independent T
and Pearson correlation tests were used to test 
differences between the groups and correlation analysis 
respectively. All Variables were quantitative and 
analyzed as parametric data using the 
package for social sciences (SPSS); version 21.0 (SPSS 
Inc; Chicago, IL, USA). The difference between groups 
was considered statistically significant when 
Figure 1. The cytokine level of caspase-1, interleukin 
patients and normal subjects. (A) Serum and cellular caspase
(B) Correlation of serum and cellular caspase
Correlation of serum caspase-1 and IL-18 level. Independent T
differences between the groups and correlation analysis respectively. 
p<0.05, **: p<0.01, ***: p<0.001. 
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Our findings showed that the caspase
significantly higher in the serum of
comparison with healthy controls (p
there was no significant difference in cellular caspase
between patients and healthy controls (
1A). Caspase-1 was higher in cells than sera in each 
studied group (p=0.022 for RRMS patients and 
p=0.004 for healthy controls) (Fig
Interestingly, our data revealed a negative correlation 
between serum and cellular caspase
individuals (p=0.049) (Figure 1B). There was no 
correlation between serum and cellular caspase
within each group (p=0.08 for RRMS patients and 
p=0.20 for healthy controls). We also identified no 
significant differences in IL-1β and IL
between patients and controls (p
respectively) (Figure 1C). There was a positive 
correlation between IL-18 and serum caspase
1(p=0.010) (Figure 1D). IL-1 and IL
measured in serum of 8 SPMS and 5 
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progressive multiple sclerosis (PPMS) patients but 
there was no significant difference between patients 




Activation of caspase-1 following the NLRP3 
inflammasome formation leads to the processing and 
secretion of IL-1β and IL-18, which are critical in the 
early steps of the inflammatory events. An important 
role for Nlrp3 components in multiple sclerosis was 
provided by studies showing that mice lacking these 
inflammasome components were protected from EAE 
development because of reduced Th1 and Th17 
responses.
6,9
 Previous studies showed that caspase-1 
absence in knockout mice mainly affects the secretion 
of pro-inflammatory cytokines such as IL-1β, IL-1α, 
IL-6, TNF-α, IL-18, and IFN- γ.10 Results also showed 
that caspase-1 transcription was up-regulated during 
mouse EAE, reaching a peak at maximal disease 
severity. 
A study on MS also showed that the level of the 
NLRP3 in patients at the remission phase after IFN-B 
therapy was significantly reduced in comparison with 
patients at the relapse phase and healthy controls.
11 
Additionally, in a very recent study, NLRP3 
inflammasome was investigated in PPMS. The results 
revealed an increased expression of NLRP3, Caspase-1, 
and the adaptor protein apoptosis-associated speck 
(ASC) in PPMS.12 
In the present study, we found that serum caspase-1 
level was significantly higher in RRMS patients in 
comparison with that in healthy controls, but no 
significant difference was detected in cellular caspase-
1, IL-1β, and IL-18 levels between patients and healthy 
controls. IL-1 and IL-18 were also measured in serum 
of 8 SPMS and 5 PPMS patients but there was no 
significant difference between patients and controls. 
Caspase-1, IL-1β, and IL-18 have been measured in 
several studies in cerebrospinal fluid (CSF) or serum of 
MS patients using different techniques with conflicting 
results so far. Some studies showed reduced levels of 
IL-1 and IL-18 whereas increased levels were reported 
by others. According to our knowledge, there is only 
one report regarding the measurement of caspase-1 in 
serum and CSF of MS patients by ELISA. This study 
showed an increase in caspase-1 level only in the CSF 
of the patients in comparison with controls.13 In another 
study, caspase-1, IL-1β, and IL-18 were measured at 
the protein and mRNA levels by western blot and real-
time PCR techniques in serum and CSF of patients who 
were not under chronic therapy of immunomodulatory 
drugs. Caspase-1 increased in all multiple sclerosis 
subtypes but IL-18 increased in the remission phase of 
RRMS and chronic progressive MS.
7
 A recent study 
has reported that mRNA expression levels of IL-1β and 
caspase-1 were significantly higher in PBMC from 
RRMS patients, while IL- 18 mRNA levels did not 
differ and in the presence of inflammasome culture 




As far as we know, there is no other study 
investigating serum and cellular caspase-1 
simultaneously. Our data revealed a negative 
correlation between serum and cellular caspase-1 in all 
studied individuals. This remarkable finding is possibly 
explained by knowing the fact that cytokines have a 
short half-life and they are generally consumed at the 
site of production or action. 
Caspase-1 is the best-described inflammatory 
factor. Caspase-1 processes the cytokines IL-1β and IL-
18 and after activation induces pyroptotic cell death. In 
response to CNS inflammation in Multiple Sclerosis 
and EAE, Caspase-1 is up-regulated in 
oligodendrocytes and initiates pyroptosis in these cells, 
a pro-inflammatory cell death. Some reports were 
suggesting that Caspase-1 may exert effects 
independent of IL-1β and IL-18 secretion.15  
In conclusion, our findings suggest that the level of 
extracellular caspase-1 which is a reflection of its 
intracellular level can be elevated in the serum of 
RRMS patients in the relapse phase and its extracellular 
level might indicate a suitable peripheral 
immunological marker of disease activity in multiple 
sclerosis. 
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